On December 4, 2025, I initiated coverage of Kura Oncology (KURA) in this article with a Speculative Buy rating. The core of that thesis was straightforward. Kura is an early commercial stage biotech.
Hosted on MSN
Alpha Tau Medical unveils strong pancreatic cancer Alpha DaRT data ahead of ASCO GI 2026
An update from Alpha Tau Medical Ltd ( (DRTS)) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its first-in-human pancreatic ductal adenocarcinoma study in Montreal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results